59 Grants (Page 2 of 3)
2016
IND 117464 Use of Low Dose Pioglitazone to Treat Autosomal Dominant Polycystic Kidney Disease
Blazer Yost, Bonnie L and Moe, Sharon M
National Institutes of Health (NIH), Food and Drug Administration (FDA) (ID: 5R01FD004826-02), $198,120USD, 07/01/2015 -- 06/30/2018
 
Pathogenesis of compromised bone quality and mechanics in chronic kidney disease.
Allen, Matthew R⋅Moe, Sharon M and Nickolas, Thomas L
National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (ID: 1R01DK110871-01), $471,810USD, 08/05/2016 -- 06/30/2020
2015
Genetic risks for cardiovascular events in ESRD patients from the EVOLVE study.
Moe, Sharon M
National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (ID: 5R01DK100306-02), $341,773USD, 08/25/2014 -- 06/30/2017
 
IND 117464 Use of Low Dose Pioglitazone to Treat Autosomal Dominant Polycystic Kidney Disease
Blazer Yost, Bonnie L and Moe, Sharon M
National Institutes of Health (NIH), Food and Drug Administration (FDA) (ID: 1R01FD004826-01A2), $199,592USD, 07/01/2015 -- 06/30/2018
 
The Mechanism of Uremia Induced Vascular Calcification
Moe, Sharon M
National Institutes of Health (NIH), Veterans Affairs (VA) (ID: 5I01BX001471-04), 04/01/2012 -- 03/31/2016
2014
Bisphosphonates in the treatment of chronic kidney disease-mineral bone disease
Moe, Sharon M
National Institutes of Health (NIH), National Institute of Arthritis and Muscoloskeletal and Skn Diseases (NIAMS) (ID: 5R01AR058005-05), $325,987USD, 04/01/2010 -- 02/28/2015
 
Genetic risks for cardiovascular events in ESRD patients from the EVOLVE study.
Moe, Sharon M
National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (ID: 1R01DK100306-01A1), $351,886USD, 08/25/2014 -- 06/30/2017
 
The Mechanism of Uremia Induced Vascular Calcification
Moe, Sharon M
National Institutes of Health (NIH), Veterans Affairs (VA) (ID: 5I01BX001471-03), 04/01/2012 -- 03/31/2016
2013
Bisphosphonates in the treatment of chronic kidney disease-mineral bone disease
Moe, Sharon M
National Institutes of Health (NIH), National Institute of Arthritis and Muscoloskeletal and Skn Diseases (NIAMS) (ID: 5R01AR058005-04), $316,008USD, 04/01/2010 -- 02/28/2015
 
The Mechanism of Uremia Induced Vascular Calcification
Moe, Sharon M
National Institutes of Health (NIH), Veterans Affairs (VA) (ID: 5I01BX001471-02), 04/01/2012 -- 03/31/2016
2012
Bisphosphonates in the treatment of chronic kidney disease-mineral bone disease
Moe, Sharon M
National Institutes of Health (NIH), National Institute of Arthritis and Muscoloskeletal and Skn Diseases (NIAMS) (ID: 5R01AR058005-03), $332,640USD, 04/01/2010 -- 02/28/2015
 
The Mechanism of Uremia Induced Vascular Calcification
Moe, Sharon M
National Institutes of Health (NIH), Veterans Affairs (VA) (ID: 1I01BX001471-01), 04/01/2012 -- 03/31/2016
2011
Bisphosphonates in the treatment of chronic kidney disease-mineral bone disease
Moe, Sharon M
National Institutes of Health (NIH), National Institute of Arthritis and Muscoloskeletal and Skn Diseases (NIAMS) (ID: 5R01AR058005-02), $332,640USD, 04/01/2010 -- 02/28/2015
 
Randomized trial of active vitamin D, cholecalciferol and placebo for CKD-MBD
Moe, Sharon M
National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (ID: 1U34DK090953-01A1), $437,593USD, 07/01/2011 -- 12/31/2012
2010
Bisphosphonates in the treatment of chronic kidney disease-mineral bone disease
Moe, Sharon M
National Institutes of Health (NIH), National Institute of Arthritis and Muscoloskeletal and Skn Diseases (NIAMS) (ID: 1R01AR058005-01A1), $338,238USD, 04/01/2010 -- 02/28/2015
 
Musculoskeletal Disorder in Dialysis Patients
Moe, Sharon M
National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (ID: 3K24DK002775-09S1), $49,917USD, 12/07/2009 -- 12/06/2010
 
Musculoskeletal Disorder in Dialysis Patients
Moe, Sharon M
National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (ID: 5K24DK002775-10), $126,412USD, 08/20/2000 -- 03/31/2012
2009
Musculoskeletal Disorder in Dialysis Patients
Moe, Sharon M
National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (ID: 5K24DK002775-09), $124,305USD, 08/20/2000 -- 03/31/2011
2008
Musculoskeletal Disorder in Dialysis Patients
Moe, Sharon M
National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (ID: 5K24DK002775-08), $122,623USD, 08/20/2000 -- 03/31/2011
2007
Musculoskeletal Disorder in Dialysis Patients
Moe, Sharon M
National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (ID: 5K24DK002775-07), $121,096USD, 08/20/2000 -- 03/31/2011
2006
Musculoskeletal Disorder in Dialysis Patients
Moe, Sharon M
National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (ID: 2K24DK002775-06A2), $119,142USD, 08/20/2000 -- 03/31/2011
2004
MUSCULOSKELETAL DISORDERS IN DIALYSIS PATIENTS
Moe, Sharon M
National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (ID: 5K24DK002775-05), $114,024USD, 08/20/2000 -- 02/28/2005
2003
MUSCULOSKELETAL DISORDERS IN DIALYSIS PATIENTS
Moe, Sharon M
National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (ID: 5K24DK002775-04), $111,699USD, 08/20/2000 -- 02/28/2005
2002
CALCIMIMETIC AGENT IN RENAL DISEASE HYPERPARATHYROIDISM
Moe, Sharon M
National Institutes of Health (NIH), National Center for Research Resources (NCRR) (ID: 5M01RR000750-30), 12/01/2001 -- 11/30/2002
 
MUSCULOSKELETAL DISORDERS IN DIALYSIS PATIENTS
Moe, Sharon M
National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (ID: 5K24DK002775-03), $109,442USD, 08/20/2000 -- 02/28/2005